Thursday, April 2, 2015

Antibiotic Executive Summary

        
       Back in 1985, my late business partner, Gerald Hirsch, Ph.D. biochemist, and I developed a theory describing a hypothetical antibiotic.  We established The Lithox Corporation to exploit this new technology.  We worked for 4 years to synthesize the molecule, but were unsuccessful, and we closed The Lithox Corporation in 1989. 

       I continued to work on this idea on my own, and 15 years later, I eventually succeeded through trial and error.  My 74th attempt yielded the correct synthetic method.  Here is a summary of my work.

  
                              A new chemical entity with antibiotic properties

I have discovered a new chemical entity with antibiotic properties that works by inhibiting the production of protein in bacteria.  This effectively stops the growth of the bacteria.

Since protein synthesis in bacteria is carried on outside of DNA, the compound does not target DNA synthesis or functions.  This means that the compound is non-mutagenic to bacteria, and that bacteria should not develop resistance to the compound as they do with antibiotics that target DNA. This is a significant characteristic of the compound.  Because human protein synthesis begins with a molecule differing from that of bacteria, the compound should not interfere with protein synthesis in humans, and therefore should have low toxicity to humans.

Because of the mutagenic properties of many existing antibiotics, bacterial resistance to their effects has developed.  More and more cases of antibiotic-resistant, flesh-eating bacteria (MSRA) are appearing in hospitals and doctors’ offices around the world, causing a significant risk to patients.  While some treatments for this problem currently exist, they can be difficult to administer, can be toxic to the human recipients, or patent protection has expired.  This NCE has the potential to solve these problems, and offer significant revenues to pharmaceutical companies.

Some of the applications for this antibacterial compound include human use for internal infections and external skin infections, veterinarian use—both in food animals and pets—and agricultural use to treat bacterial infections in plants.  It can also be used as a topical spray, and in wound coverings to prevent or treat bacterial infections, and many other uses where anti-bacterial capability is desired.

            The inventor, who already holds a number of patents, has developed a novel method to create the molecule, the compound has not been described in the scientific literature, and the antibacterial properties of the compound are unanticipated in the literature. All these factors combine to make the compound both novel and useful, each necessary for patentability.

            Initial testing has been completed in vitro on bacteria, including MRSA, and the results are good and as expected. The next stage would be wider in vitro tests, chemical characterization, and animal testing.  Patent filings would follow.

            The market potential, considering the wide variety of uses, is huge. My goal is to create an entity that subcontracts the necessary testing, files patents, and licenses the patents to various companies who will then complete the testing appropriate to their respective markets, and commercialize the compound.








No comments:

Post a Comment